News - ramucirumab

Filter

Current filters:

ramucirumab

Popular Filters

Lilly’s ramucirumab significantly improves overall survival in advanced gastric cancer patients

03-10-2013

US pharma major Eli Lilly (NYSE: LLY) has announced positive results from the Phase III REGARD trial…

Eli LillyOncologyPharmaceuticalramucirumabResearch

Mixed Phase III results with Lilly’s ramucirumab

Mixed Phase III results with Lilly’s ramucirumab

26-09-2013

US drug major Eli Lilly has announced top-line results from a global Phase III study of ramucirumab in…

Eli LillyNorth AmericaOncologyPharmaceuticalramucirumabResearch

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Eli Lilly's ramucirumab succeeds in Ph III gastric cancer study

16-10-2012

US pharma major Eli Lilly (NYSE: LLY) revealed yesterday that the REGARD trial, a Phase III study of…

Eli LillyOncologyPharmaceuticalramucirumabResearch

Back to top